Trial Profile

A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Povorcitinib (Primary)
Indications Hidradenitis suppurativa
Focus Adverse reactions; Proof of concept
Sponsors Incyte Corporation

Most Recent Events

02 Jan 2022 Results assessing safety and efficacy of INCB054707 in two multicenter trials NCT03569371 and NCT03607487 published in the British Journal of Dermatology
13 Jan 2020 Status changed from recruiting to completed.
02 Jan 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com